Large-cell transformation in MF (LCT — >25% large cells, often CD30+)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-MF-LCT |
|---|---|
| Type | Biomarker |
| Aliases | Large-cell transformationВелекоклітинна трансформація MF (LCT — >25% великих клітин, часто CD30+) |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Biomarker Facts
| Biomarker type | histology_morphology |
|---|---|
| Measurement | MethodSkin or LN biopsy review — proportion of large cells (>4× small lymphocyte size); CD30 IHC simultaneously Unitscategorical (LCT positive if ≥25% large cells | LCT negative) |
| Related biomarkers | None declared |
Notes
LCT marks aggressive transformation of MF — prognosis worsens substantially (median OS ~2-4 years from LCT diagnosis vs decades for early-stage MF). Often CD30+ (~30-50%) → eligible for brentuximab vedotin per ALCANZA trial. Mandates systemic therapy reassessment regardless of TNMB stage. Distinct from primary cutaneous CD30+ ALCL (different entity, different prognosis).
Used By
Red flag
RF-MF-LARGE-CELL-TRANSFORMATION- MF with large-cell transformation (LCT — ≥25% large cells on biopsy review) — aggressive...